Detalles de la búsqueda
1.
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update.
Diabetes Ther;
11(8): 1645-1666, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32564335
2.
Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.
Diabetes Metab Syndr;
11 Suppl 1: S91-S97, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27986406
3.
Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry.
BMJ Open Diabetes Res Care;
5(1): e000301, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28176957
4.
Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin.
Acta Diabetol;
53(5): 717-26, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27093968
5.
Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.
Ther Adv Endocrinol Metab;
5(5): 95-123, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25419451
6.
Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience.
Diabetes Technol Ther;
16(4): 241-6, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24229089
Resultados
1 -
6
de 6
1
Próxima >
>>